Open AccessRisk of Stroke and Cardiovascular Events After Ischemic Stroke or Transient Ischemic Attack in Patients With Type 2 Diabetes or Metabolic Syndrome
Author(s) -
Alfred Callahan
Publication year - 2011
Publication title -
archives of neurology
Language(s) - English
Resource type - Journals
eISSN - 1538-3687
pISSN - 0003-9942
DOI - 10.1001/archneurol.2011.146
Subject(s) - medicine , hazard ratio , stroke (engine) , diabetes mellitus , type 2 diabetes mellitus , metabolic syndrome , type 2 diabetes , cardiology , clinical endpoint , proportional hazards model , atorvastatin , revascularization , confidence interval , myocardial infarction , randomized controlled trial , endocrinology , obesity , mechanical engineering , engineering
To perform a secondary analysis of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial, which tested the effect of treatment with atorvastatin in reducing stroke in subjects with a recent stroke or transient ischemic attack, to explore the effects of treatment in subjects with type 2 diabetes mellitus or metabolic syndrome (MetS).
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom